OSCR vs ACGL vs RNR vs CLOV vs HUM

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 9. 4% for RenaissanceRe Holdings Ltd. (RNR). RenaissanceRe Holdings Ltd. (RNR) offers the better valuation at 5. 3x trailing P/E (7. 7x forward), making it the more compelling value choice. Analysts rate Arch Capital Group Ltd. (ACGL) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, RenaissanceRe Holdings Ltd.

(RNR) is the cheapest at 5. 3x versus Humana Inc. at 25. 1x. On forward P/E, RenaissanceRe Holdings Ltd. is actually cheaper at 7. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: RenaissanceRe Holdings Ltd. wins at 0. 26x versus Arch Capital Group Ltd. 's 0. 35x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Arch Capital Group Ltd.

(ACGL) delivered a total return of +144. 0%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ACGL returned +324. 0% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), RenaissanceRe Holdings Ltd.

(RNR) is the lower-risk stock at -0. 03β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately -5878% more volatile than RNR relative to the S&P 500. On balance sheet safety, Arch Capital Group Ltd. (ACGL) carries a lower debt/equity ratio of 11% versus 73% for Humana Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus 9. 4% for RenaissanceRe Holdings Ltd. (RNR). On earnings-per-share growth, the picture is similar: RenaissanceRe Holdings Ltd. grew EPS 60. 8% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arch Capital Group Ltd.

(ACGL) is the more profitable company, earning 22. 1% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 22. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNR leads at 31. 5% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — RNR leads at 40. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, RenaissanceRe Holdings Ltd. (RNR) is the more undervalued stock at a PEG of 0. 26x versus Arch Capital Group Ltd. 's 0. 35x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, RenaissanceRe Holdings Ltd. (RNR) trades at 7. 7x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 58. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 18. 1% to $3. 33.

In this comparison, HUM (1.

4% yield), RNR (0. 6% yield) pay a dividend. OSCR, ACGL, CLOV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, RenaissanceRe Holdings Ltd.

(RNR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 03), 0. 6% yield, +176. 9% 10Y return). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNR: +176. 9%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OSCR (Healthcare) and ACGL (Financial Services) and RNR (Financial Services) and CLOV (Healthcare) and HUM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OSCR is a small-cap high-growth stock; ACGL is a mid-cap deep-value stock; RNR is a mid-cap deep-value stock; CLOV is a small-cap high-growth stock; HUM is a mid-cap quality compounder stock. RNR, HUM pay a dividend while OSCR, ACGL, CLOV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.